Dieter H.
- Country
- Germany
- Department
- Klinik für Innere Medizin/Gastroenterologie und Endokrinologie
Research Overview
- Phase III Study on the Efficacy and Safety of 177Lu-Edotreotide PRRT Versus Everolimus in Inoperable, Progressive SSTR+ GEP-NET Patients
- Evaluation of Ramucirumab and Dacarbazine Efficacy in Progressive Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumors
- Phase II Evaluation of Cabozantinib in Advanced Low Proliferative Grade 3 Neuroendocrine Neoplasms
Data & Insights
Has run more than one trial at 39 of 97 partner sites.
Specializations
Neuroendocrine Oncology
This investigator specializes in treating neuroendocrine neoplasias and neuroendocrine tumors, with particular expertise in managing advanced and progressive disease states.
- Advanced NEN G3 Management
- Novel Therapeutic Approaches
- Progressive Disease Treatment
Their research encompasses innovative treatment strategies for patients with advanced neuroendocrine conditions.
Pancreatic Oncology
The investigator focuses on treating progressive well-differentiated metastatic neuroendocrine tumors of the pancreas, exploring combination therapy approaches for optimal disease control.
- Metastatic Disease Management
- Combination Therapy Development
- Pancreatic NET Treatment
Their work involves evaluating novel therapeutic combinations for pancreatic neuroendocrine tumors.
Gastroenteropancreatic NET
Specialized in treating neuroendocrine tumours of gastroenteric or pancreatic origin, with expertise in advanced therapeutic modalities including peptide receptor radionuclide therapy.
- PRRT Applications
- GEP-NET Treatment
- Comparative Therapy Assessment
Their research extends to evaluating survival outcomes in patients with inoperable, progressive NET conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.